TARRYTOWN, N.Y. — The novel coronavirus arrived at Regeneron Pharmaceuticals’ sprawling campus like any other parcel.

Inside a cardboard box, shipped to the company’s scientists, was a small tube. And inside it was a fragment of genetic code belonging to 2019-nCoV, the infectious agent that has killed more than 400 people since the start of the outbreak in China. Because it was just a snippet of the full genome, the virus wasn’t actually infectious.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • It is MERCK’s Ebola vaccine that was succesfully tested in the outbreak in the Congo in 2019, and got FDA approval later in 2019. J & J is still testing a 2-dose version (why?). Regeneron’s is only still in development. To save its huge R & D investment, now Regeneron is re-directing its R & D to the China Co-V (let’s just give it a proper name, shall we?). And that might be a good thing – but does not warrant this article’s overblown hoopla. There are also several other companies in the running, that the article fails to mention.

    • Merck is the only VACCINE approved. Regeneron is 100% the most effective TREATMENT as demonstrated by the trial in the congo.

    • They already put in the investment years ago to make the humanized mouse, and it’s how they generate their mAbs for everything. The point of the article was to highlight that generating mAbs in a humanized mouse is faster/more efficient than doing so in a regular mouse and then pasting the CDRs into a human mAb. Perfect for rapid response to disease/virus outbreaks (and for generating “me too” drugs like Libtayo.

  • Very informative. Surprised to hear that profit is not the driving force. But yes, let’s get cooking on this. Time is of the essence, especially for first responders and health care workers.

  • Kudos to all these biotech companies. It seems that the novel coronavirus is here to stay like common cold, so their effort will not be wasted.

Your daily dose of news in health and medicine

Privacy Policy